Cargando…

Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance

PD-L1 expression may be a predictive marker for anti-PD-1 therapeutic efficacy. No standard detection method of PD-L1 expression was available for advanced gastric cancer (AGC), which would be investigated in this study using RNA in situ hybridization and immunohistochemistry. Patients (N = 165) wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Jiajia, Zhang, Jie, Zhu, Yan, Li, Na, Tian, Tiantian, Li, Yang, Li, Yanyan, Li, Zhongwu, Lai, Yumei, Gao, Jing, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129961/ https://www.ncbi.nlm.nih.gov/pubmed/27191996 http://dx.doi.org/10.18632/oncotarget.9381

Ejemplares similares

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas
por: Wu, Yan, et al.
Publicado: (2021)

The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer
por: Wei, Xiao-Li, et al.
Publicado: (2021)

Four-color fluorescence in-situ hybridization is useful to assist to distinguish early stage acral and cutaneous melanomas from dysplastic junctional or compound nevus
por: Lai, Yumei, et al.
Publicado: (2020)

Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Tian, Tiantian, et al.
Publicado: (2016)

Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Risk prediction for early-onset gastric carcinoma: a case-control study of polygenic gastric cancer in Han Chinese with hereditary background
por: Yuan, Jiajia, et al.
Publicado: (2016)

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
por: Chen, Zuhua, et al.
Publicado: (2022)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
por: Chen, Zuhua, et al.
Publicado: (2018)

Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma
por: Xu, Yingying, et al.
Publicado: (2015)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer
por: Noh, Myung-Giun, et al.
Publicado: (2021)

The significance of programed cell death‐ligand 1 expression in vestibular schwannoma
por: Lee, Se A, et al.
Publicado: (2023)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
por: Liang, Yuehua, et al.
Publicado: (2022)

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
por: Pal, Krishnendu, et al.
Publicado: (2022)

Diagnostic value of negative enrichment and immune fluorescence in situ hybridization for intraperitoneal free cancer cells of gastric cancer
por: Wang, Anqiang, et al.
Publicado: (2019)

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
por: Kim, Hye Ryun, et al.
Publicado: (2017)

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
por: Wu, Shafei, et al.
Publicado: (2017)

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
por: Tominaga, Tetsuro, et al.
Publicado: (2019)

Clinical significance of soluble programmed cell death‐ligand 1 in hepatitis B virus‐related hepatocellular carcinoma
por: Yang, Zhongxia, et al.
Publicado: (2023)

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
por: Park, Woochan, et al.
Publicado: (2021)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges
por: Yamashita, Kohei, et al.
Publicado: (2020)

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
por: Chen, Zuhua, et al.
Publicado: (2020)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer
por: Yu, Hung-Yuan, et al.
Publicado: (2022)

Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer
por: Shen, Bo, et al.
Publicado: (2019)

Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients
por: Chen, Xinhua, et al.
Publicado: (2022)

The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients
por: Shen, Haixiang, et al.
Publicado: (2020)

Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
por: Zhang, Ying, et al.
Publicado: (2017)

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
por: Mikami, Shuji, et al.
Publicado: (2019)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers
por: Tang, Yating, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_73mt8s8tvbqhu81bn8qt8f8qui